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NEW ADVANCES IN CYSTIC
FIBROSIS - IMPLICATIONS FOR
DEVELOPING COUNTRIES
There has been substantial progress in the understanding of
cystic fibrosis (CF) in the past decade. The discovery of the
gene in 1989 provided an important impetus to understanding
the molecular basis of CF a.'1d its pathogenesis, and offered a
means of diagnosing the disease. Perhaps more importantly it
broadened our concept of the clinical spectrum of CF and gave
rise to new options for treating this potentially devastating
disease.
CF is caused by a mutation in a single gene on the long arm
of chromosome 7 that encodes the cystic fibrosis
transmembrane regulator (CFfR)l The basic defect in CF is an
alteration in the regulation of ion transport across the apical
membranes of epithelial cells. Mutations in the CF gene
produce dysfunctional or absent CFTR, resulting in defective
chloride and sodium absorption in the respiratory, gastro-
intestinal and reproductive tracts.' To date over 700 mutations
have been reported, the most common of which is the M508
mutation, present in 82% and 53% of CF genes of white
(European origin) and coloured (mixed ancestry) South African
patients, respectively.' This mutation has not been identified in
black South Africans, in whom other mutations, such as
3120+1G->A, predominate. This mutation was shown to be
present in 4 out of 6 CFTR genes from 3 black CF patients'
Studies on the carrier status of healthy black South Africans
indicate that CF is likely to be much more common in this
population than was formerly recognised5 Genotyping has
thus afforded a broader view of the extent of CF in the South
African population and has improved the accuracy of prenatal
diagnosis and genetic counselling. Although the sweat test
remains the standard method for diagnosis, genotyping has
improved the ability to diagnose CF, particularly when the
clinical presentation is atypical or the sweat test normal or
equivocal.'
Respiratory disease is the primary cause of morbidity and
mortality in CF. Lung disease results from two processes -
chronic endobronchial infection and neutrophil-dominated
airway inflammation. Conventional therapy has focused on
clearance of lower airway secretions (using physiotherapy
techniques and bronchodilators), antibiotic administration and
maintenance of adequate nutrition (using pancreatic enzyme
replacements and nutritional supplements). Several new and
effective therapies for CF lung disease have been developed.7
For chronic endobronchial Pseudomonas aeruginosa infection,
aerosolised antibiotic therapy, particularly the aminoglycosides,
has resulted in improved pulmonary function, reduced need
for intravenous antibiotics and decreased duration of
hospitalisation.s" The development of quinolone antibiotics,
principally ciprofloxacin, has offered an effective oral therapy
for susceptible P aeruginosa lO Anti-inflammatory therapy with
ibuprofen may slow the progression of CF lung disease by
reducing airway inflammation, particularly when used in
young patients with mild disease. l1 Inhaled recombinant
human deoxyribonuclease (rhDNase I), a treatment that
decreases sputum viscosity by cleaving extracellular DNA
originating from inflammatory cells, has reduced the frequency
of severe respiratory exacerbations and the annual
deterioration in pulmonary function." Recent data suggest that
nebulised hypertonic saline may produce similar
improvements in lung function, although further confirmation
of this is awaited. l3 Lung transplantation, an option for CF
patients with end-stage pulmonary disease in some overseas
centres, may improve both quality of life and survival."
Although this has been performed in South Africa, cost and
lack of experience in postoperative care of these patients may
limit the success of this procedure.
Potential future therapies for CF lung disease include other
anti-inflammatory agents, modulators of ion transport, and
gene replacement therapy. Aerosolised anti-proteases such as
secretory leucocyte protease inhibitor and a,-antitrypsin may
prevent lung damage resulting from neutrophil elastase.
Inhibitors of neutrophil chemotaxis such as pentoxifylline may
prevent the influx of neutrophils and the development of florid
airway inflammation and lung injury. Activators of alternative
chloride channels such as uridine triphosphate, or sodium
channel antagonists such as arniloride, may normalise the
defect in ion secretion and absorption. Gene therapy in the
form of adenoviral vectors and liposomes has been used to
deliver the complementary DNA for CFTR into the respiratory
tract of adults with CFls Although it appears that the CFTR
gene can be transduced into the respiratory epithelium using
either of these methods, the clinical benefit, duration of effect,
long-term outcome and side-effects of such therapy await full
evaluation.
Although the development of new therapies has improved
the outlook of patients with CF, the major impact on survival
has resulted from the application of standard, conventional
treatmellts given early in the disease. Key factors influencing
prognosis include early diagnosis, maintenance of optimal
nutrition and aggressive treatment of pulmonary infections.
Patients diagnosed and referred to a CF centre before the age of
1 year have better lung function at 14 years than those I':'PJCJI
diagnosed later!' - timely diagnosis and referral of CF ~
patients is therefore essential. The impact of P. aeruginosa
infection on lung function is apparent from the accompanying
paper by Zar et al.,!7 and the benefit of antipseudomonal
treatment has been demonstrated in a number of studies.7".!S
The ability of the community or patient to afford relatively
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costly long-term, lifelong care also impacts directly on
outcome. ewer treatments such as rhD ase appear to offer
improved outcome, but at considerable additional cost.
The question of what should be considered minimal
acceptable treatment of CF in developing countries is an
evocative and controversial question. Firstly, the value of a CF
centre where a multidisciplinary team including doctors,
physiotherapists, nutritionists and social workers can provide
support for all the important aspects of this disease must be
emphasised. These clinics require co-ordination and a suitable
location in large regional centres. Secondly, provision of
standard conventional therapy including antibiotics, pancreatic
enzyme replacement therapy and nutritional support needs to
be assured, as these constitute basic care for CF patients.
Thirdly, treatment for CF-associated complications such as
diabetes should be provided. It is gratifying to note that the
prognosis for South African children, although not as good as
for orth American patients," has improved significantly with
this approach.'" As a result the majority of CF patients born in
1998 can be expected to survive into adulthood. A consensus
document on the care of CF patients is currently being
compiled by the medical and scientific advisory committee of
the South African Cystic Fibrosis Association (SACFA), and
will soon be available.
Assurance of continued lifelong care is a serious concern for
all patients with chronic diseases, particularly for those who,
like CF sufferers, require a variety of costly drugs. The cost of
rhD ase, transplantation, and in time possibly gene therapy
place these treatments beyond the reach of State funding, but
may be accommodated within the cover of some private
medical aid schemes. CF clinics and support groups need to
continue their important advocacy role in ensuring continued
governmental, medical aid and private support.
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